Long-Acting Buprenorphine Medications as a Novel Pharmacological Option in Opioid Dependence

被引：1

作者：

Soyka, Michael ^{[1
,2
]}

机构：

[1] Med Pk Chiemseeblick, Rasthausstr 25, D-83233 Bernau Felden, Germany

[2] Psychiat Univ Klin LMU Munchen, Munich, Germany

来源：

SUCHTTHERAPIE | 2020年 / 21卷 / 01期

关键词：

opioid dependence; maintenance treatment; buprenorphine; depot; implant; SUSTAINED-RELEASE FORMULATION; FOLLOW-UP; METHADONE-MAINTENANCE; USE DISORDER; HEROIN; ADDICTION; RETENTION; MORTALITY; BLOCKADE; RBP-6000;

D O I：

10.1055/a-1064-6188

中图分类号：

R749 [精神病学];

学科分类号：

100205 ;

摘要：

Opioid maintenance treatment with oral methadone or sublingual buprenorphine is an established first-line treatment in opioid dependence. Both drugs must be taken daily (methadone) or at least every second day (buprenorphine). Apart from the novel subcutaneous weekly and monthly depot formulations CAM 2038 (Buvidal (R)) 2 other long-acting buprenorphine formulations may be introduced in the near future: the monthly depot formulation RBP-6000 (Sublocade (TM)) and a 6-month buprenorphine implant (Probuphine (TM)). Clininical findings of these three medications are given and possible clinical indications are discussed.

引用

页码：13 / 18

页数：6

共 50 条

[21] Treatment continuation of four long-acting antipsychotic medications in the Netherlands and Belgium: A retrospective database study
Decuypere, Flore
Sermon, Jan
Geerts, Paul
Denee, Tom R.
De Vos, Cedric
Malfait, Bart
Lamotte, Mark
Mulder, Cornelis L.
PLOS ONE, 2017, 12 (06):
[22] Long-acting depot buprenorphine in people who are homeless: Views and experiences
Matheson, Catriona
Foster, Rebecca
Schofield, Joe
Browne, Tania
JOURNAL OF SUBSTANCE ABUSE TREATMENT, 2022, 139
[23] Physiologic and behavioral effects of long-acting subcutaneous and transdermal buprenorphine in rats
Collins, Elijah J.
Zhao, Qianqian
Baker, Tracy L.
Johnson, Rebecca A.
AMERICAN JOURNAL OF VETERINARY RESEARCH, 2024, 85 (10)
[24] A Population Pharmacokinetic and Pharmacodynamic Modelling Approach to Support the Clinical Development of RBP-6000, a New, Subcutaneously Injectable, Long-Acting, Sustained-Release Formulation of Buprenorphine, for the Treatment of Opioid Dependence
Azmi F. Nasser
Christian Heidbreder
Roberto Gomeni
Paul J. Fudala
Bo Zheng
Mark K. Greenwald
Clinical Pharmacokinetics, 2014, 53 : 813 - 824
[25] A novel long-acting formulation of oral buprenorphine/naloxone produces prolonged decreases in fentanyl self-administration by rhesus monkeys
Foltin, Richard W.
Zale, Stephen
Sykes, Kristine A.
Nagaraj, Nayana
Scranton, Richard E.
Comer, Sandra D.
DRUG AND ALCOHOL DEPENDENCE, 2022, 239
[26] Tracing the affordances of long-acting injectable depot buprenorphine: A qualitative study of patients' experiences in Australia
Barnett, Anthony
Savic, Michael
Lintzeris, Nicholas
Bathish, Ramez
Arunogiri, Shalini
Dunlop, Adrian J.
Haber, Paul
Graham, Robert
Hayes, Vicky
Lubman, Dan, I
DRUG AND ALCOHOL DEPENDENCE, 2021, 227
[27] Conceptualising retention in treatment with long-acting injectable buprenorphine (for opioid use disorder) as a journey: Findings from a longitudinal qualitative study
Parkin, Stephen
Neale, Joanne
Strang, John
INTERNATIONAL JOURNAL OF DRUG POLICY, 2023, 122
[28] Predictors of availability of long-acting medication for opioid use disorder
Shover, Chelsea L.
Humphreys, Keith
DRUG AND ALCOHOL DEPENDENCE, 2019, 204
[29] Long-acting injectable buprenorphine in the real world: case report on dual disorders
Palma-Alvarez, Raul Felipe
Ortega-Hernandez, German
Roch-Santed, Maria
Ramos-Quiroga, Josep Antoni
Grau-Lopez, Lara
JOURNAL OF ADDICTIVE DISEASES, 2024,
[30] Impact of long-acting buprenorphine injection on methamphetamine use: A retrospective cohort study
Raza, M.
Abeysundera, H.
Branjerdporn, G.
AUSTRALASIAN PSYCHIATRY, 2023, 31 (05) : 690 - 693

← 1 2 3 4 5 →